Investigation of the cell based therapy for primary lung dysfunction after lung transplantation using mesenchymal stem cell
Project/Area Number |
26870042
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
General surgery
Respiratory surgery
|
Research Institution | Tohoku University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 肺移植 / 細胞治療 / 虚血再灌流障害 / 間葉系幹細胞 / 胸部外科 / 移植 / 臓器保存 |
Outline of Final Research Achievements |
Primary graft dysfunction is a major cause of morbidity and mortality after lung transplantation. Mesenchymal stem cells (MSCs) have a suppress inflammation and immune responses. We examined whether MSCs attenuate ischemia-reperfusion injury in a mouse model of lung transplantation. Mouse lungs were preserved at 4°C for 18 h. Human MSCs were injected into the lung grafts, and orthotopic left lung transplantation was performed. The lung isografts were reperfused for 6 hours. Protein concentration and cell count in Bronchioalveolar lavage fluid were significantly lower in the MSC-administered grafts than in the PBS-administered controls. Concentrations of proinflammatory cytokines showed a decreasing trend in the MSC-administered grafts compared with the controls.Pretransplant administration of MSC may attenuate ischemia-reperfusion injury after prolonged cold ischemia in the mouse model of lung transplantation.
|
Report
(3 results)
Research Products
(1 results)